12th International Congress on Myeloproliferative Neoplasms

 

12th International Congress on Myeloproliferative Neoplasms
J

66 y/o Female w/ Systemic Mastocytosis Associated with CEL: Clinical Efficacy of KIT Inhibitors, Potential Role of HSCT

By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jason R. Gotlib
By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jason R. Gotlib
0 views
November 25, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Cases
06:02
12th International Congress on Myeloproliferative Neoplasms

66 y/o Female w/ Aggressive Systemic Mastocytosis: AHNs Are Under-Di…

Feat. J. Gotlib
02:58
12th International Congress on Myeloproliferative Neoplasms

73 y/o Male w/ Aggressive Systemic Mastocytosis: High-Sensitive Assa…

Feat. J. Gotlib
03:11
12th International Congress on Myeloproliferative Neoplasms

73 y/o Male w/ SM-AHM: Work Through Whether SM or AHN Is the Major C…

Feat. J. Gotlib
04:59
12th International Congress on Myeloproliferative Neoplasms

68 y/o Female w/ Systemic Mastocytosis with Chronic Myelomonocytic L…

Feat. J. Gotlib
02:43
12th International Congress on Myeloproliferative Neoplasms

28 y/o Female w/ Well-Differentiated Systemic Mastocytosis: Imatinib…

Feat. J. Gotlib
07:53
12th International Congress on Myeloproliferative Neoplasms

66 y/o Female w/ Systemic Mastocytosis Associated with CEL: Clinical…

Feat. J. Gotlib